Redeye makes minor adjustements to its valuation of InDex Pharmaceuticals following the announcement...
Q4e: Two deliveries, sales only SEK 3.6m due to payment model '24e the year of e-MELT ID, '25e the y...
The Palex group of 800 professionals with a long history as a leading provider of advanced solutions...
We update our model after recent share issues... ..
Etteplan gave a profit warning as its EBIT fell short of expectations in Q4.
Duell's results exceeded our estimates for revenue and adj.
Q4'23 results due 6 February Instrument sales to drive growth in Q4e 27-33% below historical NTM P/E...
Q4e: sales of SEK 30m, up 37% y-o-y, adj. EBIT SEK -5m (-20m) Turning our eyes to '24e, where we exp...
Expect strong Q4 sales after order intake surprise in Q3 Estimates unchanged, growth and margin expa...
Q4e: sales SEK 50m, up +9% q-o-q, EBIT -2m (-4m) Minor estimate changes, eyeing profitable growth in...
Redeye summarizes the highlights of CLS’ business update event.
Redeye believes the offer from Matrix42 of EUR15 in cash per share is fair, considering the 91% prem...
Duell was able to grow its revenue 4.9% y/y during the seasonally slow Q1 as inorganic growth suppor...
Prostatype Genomics secured SEK 25m in growth capital in the latest right issue.
Q4 report due Thursday, 8 February at 07:00 CET '23e-'25e EBITA down 3-1%; 10% CAGR '22-'25e 12-10x ...
Q4e: sales SEK 32m, up 6.4% y-o-y, EBIT margin of 21.
Q4e: Cost cuts and price hikes lift earnings Minor estimate changes, EBITA +1% on FX Trading at 11x ...
Redeye comments on the slightly improved data, which are becoming mature, from the latest readout of...
Redeye leaves its forecasts for Q4 and 2024 roughly unchanged and comments on the change in Autodesk...
Redeye updates its estimates for the Q4 2023 report (due 1 February 2024) with lower sales estimates...
